Cargando…

Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design

Mirtazapine is a tetracyclic anti-depressant with poor water solubility. The aim of this study was to improve the dissolution rate of mirtazapine by delivering the drug as a liquisolid compact. Central composite design (CCD) was employed for the preparation of mirtazapine liquisolid compacts. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Naureen, Faiza, Shah, Yasar, Shah, Sayyed Ibrahim, Abbas, Muhammad, Rehman, Inayat Ur, Muhammad, Salar, , Hamdullah, Goh, Khang Wen, Khuda, Fazli, Khan, Amjad, Chan, Siok Yee, Mushtaq, Mehwish, Ming, Long Chiau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268088/
https://www.ncbi.nlm.nih.gov/pubmed/35807252
http://dx.doi.org/10.3390/molecules27134005
_version_ 1784743894251995136
author Naureen, Faiza
Shah, Yasar
Shah, Sayyed Ibrahim
Abbas, Muhammad
Rehman, Inayat Ur
Muhammad, Salar
, Hamdullah
Goh, Khang Wen
Khuda, Fazli
Khan, Amjad
Chan, Siok Yee
Mushtaq, Mehwish
Ming, Long Chiau
author_facet Naureen, Faiza
Shah, Yasar
Shah, Sayyed Ibrahim
Abbas, Muhammad
Rehman, Inayat Ur
Muhammad, Salar
, Hamdullah
Goh, Khang Wen
Khuda, Fazli
Khan, Amjad
Chan, Siok Yee
Mushtaq, Mehwish
Ming, Long Chiau
author_sort Naureen, Faiza
collection PubMed
description Mirtazapine is a tetracyclic anti-depressant with poor water solubility. The aim of this study was to improve the dissolution rate of mirtazapine by delivering the drug as a liquisolid compact. Central composite design (CCD) was employed for the preparation of mirtazapine liquisolid compacts. In this, the impacts of two independent factors, i.e., excipient ratio (carrier:coating) and different drug concentration on the response of liquisolid system were optimized. Liquisolid compacts were prepared using propylene glycol as a solvent, microcrystalline cellulose as a carrier, and silicon dioxide (Aerosil) as the coating material. The crystallinity of the formulated drug and the interactions between the excipients were examined using X-ray powder diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR), respectively. The dissolution study for the liquisolid compact was carried out as per FDA guidelines. The results showed loss of crystallinity of the mirtazapine in the formulation and was completely solubilized in non-volatile solvent and equally dispersed throughout the powder system. Moreover, drug dissolution was found to be higher in liquisolid compacts than the direct compressed conventional tablets (of mirtazapine). The liquisolid technique appears to be a promising approach for improving the dissolution of poorly soluble drugs like mirtazapine.
format Online
Article
Text
id pubmed-9268088
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92680882022-07-09 Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design Naureen, Faiza Shah, Yasar Shah, Sayyed Ibrahim Abbas, Muhammad Rehman, Inayat Ur Muhammad, Salar , Hamdullah Goh, Khang Wen Khuda, Fazli Khan, Amjad Chan, Siok Yee Mushtaq, Mehwish Ming, Long Chiau Molecules Article Mirtazapine is a tetracyclic anti-depressant with poor water solubility. The aim of this study was to improve the dissolution rate of mirtazapine by delivering the drug as a liquisolid compact. Central composite design (CCD) was employed for the preparation of mirtazapine liquisolid compacts. In this, the impacts of two independent factors, i.e., excipient ratio (carrier:coating) and different drug concentration on the response of liquisolid system were optimized. Liquisolid compacts were prepared using propylene glycol as a solvent, microcrystalline cellulose as a carrier, and silicon dioxide (Aerosil) as the coating material. The crystallinity of the formulated drug and the interactions between the excipients were examined using X-ray powder diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR), respectively. The dissolution study for the liquisolid compact was carried out as per FDA guidelines. The results showed loss of crystallinity of the mirtazapine in the formulation and was completely solubilized in non-volatile solvent and equally dispersed throughout the powder system. Moreover, drug dissolution was found to be higher in liquisolid compacts than the direct compressed conventional tablets (of mirtazapine). The liquisolid technique appears to be a promising approach for improving the dissolution of poorly soluble drugs like mirtazapine. MDPI 2022-06-22 /pmc/articles/PMC9268088/ /pubmed/35807252 http://dx.doi.org/10.3390/molecules27134005 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naureen, Faiza
Shah, Yasar
Shah, Sayyed Ibrahim
Abbas, Muhammad
Rehman, Inayat Ur
Muhammad, Salar
, Hamdullah
Goh, Khang Wen
Khuda, Fazli
Khan, Amjad
Chan, Siok Yee
Mushtaq, Mehwish
Ming, Long Chiau
Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design
title Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design
title_full Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design
title_fullStr Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design
title_full_unstemmed Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design
title_short Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design
title_sort formulation development of mirtazapine liquisolid compacts: optimization using central composite design
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268088/
https://www.ncbi.nlm.nih.gov/pubmed/35807252
http://dx.doi.org/10.3390/molecules27134005
work_keys_str_mv AT naureenfaiza formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT shahyasar formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT shahsayyedibrahim formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT abbasmuhammad formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT rehmaninayatur formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT muhammadsalar formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT hamdullah formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT gohkhangwen formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT khudafazli formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT khanamjad formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT chansiokyee formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT mushtaqmehwish formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign
AT minglongchiau formulationdevelopmentofmirtazapineliquisolidcompactsoptimizationusingcentralcompositedesign